Compare WPRT & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WPRT | CCEL |
|---|---|---|
| Founded | 1995 | 1989 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Managed Health Care |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 30.9M |
| IPO Year | 2006 | 2022 |
| Metric | WPRT | CCEL |
|---|---|---|
| Price | $1.77 | $3.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $4.38 | N/A |
| AVG Volume (30 Days) | ★ 65.4K | 10.9K |
| Earning Date | 04-23-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 4.26% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.74 | N/A |
| P/E Ratio | ★ N/A | $48.00 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $1.54 | $2.72 |
| 52 Week High | $3.88 | $5.43 |
| Indicator | WPRT | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 47.71 |
| Support Level | $1.57 | $3.33 |
| Resistance Level | $1.85 | $3.92 |
| Average True Range (ATR) | 0.08 | 0.27 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 35.48 | 31.88 |
Westport Fuel Systems Inc is an organization engaged in the engineering, manufacturing, and supply of alternative fuel systems and components for transportation applications. It has three reportable segments: High-Pressure Controls, Heavy-Duty OEM, and Cespira. It derives maximum revenue from Heavy-Duty OEM segment. Heavy-Duty OEM segment's products include HPDI related fuel system solutions and components. Geographically, the company operates in Europe, America and Asia, of which it generates maximum revenue from Europe. It also develops and supplies advanced LPG, CNG, LNG and H2 systems and components for OEM (original equipment manufacturer) D-OEM (delayed oem) and After Market (retrofit market) world-wide.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.